HDAC9 and peripheral T-cell lymphoma, not otherwise specified: Two out of the remaining seven identified AspH inhibitors were histone deacetylase (HDAC) inhibitors, both bearing a hydroxamate functional group, which inhibited > 90% AspH activity at 20 μM: the HDAC6-selective inhibitor tubacin48 (Table 1, entry 7) and the broad-spectrum HDAC inhibitor belinostat (PXD101)45 (Table 1, entry 5), which is an approved API for the treatment of relapsed or refractory peripheral T-cell lymphoma.59